HONG KONG – Japan could welcome nine biosimilar drugs to the market in the coming years, thanks to a commercialization deal between Amgen Inc. and local company Daiichi Sankyo Co. Ltd. The Thousand Oaks, Calif.-based pharma major said it inked a deal with Daiichi Sankyo to bring nine of its biosimilar drugs, some now undergoing late-stage clinical studies, to the Japanese market.